PD-1 Monoclonal Antibody Patent Application for Cancer Treatment
Summary
The USPTO published patent application US20260098092A1 for monoclonal antibodies targeting human programmed cell death protein 1 (PD-1) and methods for treating cancer using said antibodies and antigen-binding fragments. The application was filed October 4, 2023, naming seven inventors including Trairak Pisitkun and colleagues. Pharmaceutical and biotech companies developing PD-1/PD-L1 pathway cancer immunotherapies should monitor for this application's progression to grant.
What changed
The USPTO published patent application US20260098092A1 covering monoclonal antibodies that bind specifically to human PD-1 and methods for treating cancer or other diseases with said antibodies and antigen-binding fragments.
Pharmaceutical and biotech companies developing cancer immunotherapies targeting the PD-1/PD-L1 pathway should monitor this application for potential freedom-to-operate concerns, competitive landscape implications, and to assess whether their R&D programs may infringe claims if the patent issues.
What to do next
- Monitor for updates on patent application progression
- Review for prior art in PD-1/PD-L1 immunotherapy development
Archived snapshot
Apr 10, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
MONOCLONAL ANTIBODIES AGAINST HUMAN PROGRAMMED CELL DEATH PROTEIN 1 (PD-1)
Application US20260098092A1 Kind: A1 Apr 09, 2026
Inventors
Trairak Pisitkun, Chatikorn Boonkrai, Tossapon Wongtangprasert, Tanapati Phakham, Thittaya Audomsun, Chadaporn Attakitbancha, Pijitra Saelao
Abstract
The present disclosure relates to antibodies and anti-gen-binding fragments that bind specifically to the human programmed cell death protein 1 (PD-1) and methods for treating cancer or other diseases with said antibodies and antigen-binding fragments.
CPC Classifications
C07K 16/2818 A61P 35/00 A61K 2039/505 C07K 2317/24 C07K 2317/52 C07K 2317/565 C07K 2317/76 C07K 2317/92
Filing Date
2023-10-04
Application No.
19114741
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.